Dyslipidemia (DLP) in Older Adults: A Guide to Ordering Medications Using Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin, Ezetimibe, Fenofibrate, Omega-3 FA
1. Basic Dyslipidemia Medication Orders (No Ranges)
| Medication | Example Order | Short Note |
|---|---|---|
| Simvastatin | Simvastatin (20) 1×1 PO HS | Monitor LFTs/lipids; watch for myalgias. |
| Atorvastatin | Atorvastatin (40) 1×1 PO HS | Useful in primary/secondary prevention. |
| Rosuvastatin | Rosuvastatin (10) 1×1 PO OD | Caution with higher doses in Asian patients. |
| Pravastatin | Pravastatin (20) 1×1 PO HS | Fewer drug interactions; often chosen for elderly or polypharmacy. |
| Ezetimibe (Add-On) | Ezetimibe (10) 1×1 PO OD | Combine with statin if LDL remains high. |
| Fenofibrate (TG >500) | Fenofibrate (160) 1×1 PO OD | For high TG; avoid gemfibrozil + statin combo. |
| Omega-3 FA (TG >500) | Omega-3 (1000) 2 caps PO OD | ~2 g/day total EPA/DHA; helps reduce TG. |
Key
- PO = by mouth
- HS = at bedtime
- OD = once daily
Monitor:
- Check lipid panel in ~4–12 weeks after starting or adjusting therapy.
- LFTs (AST/ALT) at baseline and 1–3 months if indicated.
- Counsel on muscle symptoms; if severe, check CK and consider holding statin or lowering dose.
2. Extended Table: Starting Dose & Maximum Dose
| Medication | Starting Dose | Maximum Dose | Short Note |
|---|---|---|---|
| Simvastatin | 20 mg PO HS | 40 mg PO HS | Higher doses (e.g., 80 mg) generally not recommended due to increased myopathy risk. |
| Atorvastatin | 20 mg PO HS | 80 mg PO HS | High-intensity statin if needed; check LFTs and CK if symptoms arise. |
| Rosuvastatin | 10 mg PO OD | 40 mg PO OD | Often limit to 20 mg in Asian patients, but official max is 40 mg. |
| Pravastatin | 20 mg PO HS | 40 mg PO HS | Less potent; sometimes escalated to 40 mg if inadequate LDL response. |
| Ezetimibe (Add-On) | 10 mg PO OD | 10 mg PO OD | One dose only; usually combined with statin for additional LDL lowering. |
| Fenofibrate (TG >500) | 160 mg PO OD | 200 mg PO OD (depending on formulation) | Micronized fenofibrate formulations vary; typical “max” is ~200 mg/day. |
| Omega-3 FA (TG >500) | 2 g/day (split: 1000 mg × 2) | 4 g/day (split doses) | Pharmaceutical-grade EPA/DHA. Monitor for GI upset, fishy aftertaste. |
Key
- PO = by mouth
- HS = at bedtime
- OD = once daily
Practice Points:
- Adjust doses based on LDL goals, patient tolerance, and follow-up lipid panel in 1–3 months.
- In older adults or those with multiple comorbidities, start at lower doses (or moderate intensity) and monitor closely.
Introduction
Managing dyslipidemia in older adults requires risk assessment, appropriate drug selection and dosing, and monitoring for side effects. This guide summarizes the key steps for prescribing medications safely and effectively.
1. Assessing Cardiovascular Risk
- Thai CV Risk Score (for ages 35–70 without known CVD)
- Estimates 10-year risk. High-risk if ≥10% or presence of significant risk factors (e.g., diabetes, CKD, hypertension).
- Existing Cardiovascular Disease (CVD)?
- Already qualifies for secondary prevention with statin therapy.
2. Pre-Treatment Assessment and Monitoring
- Baseline Labs:
- Fasting lipid panel (Total cholesterol, LDL-C, HDL-C, Triglycerides)
- Liver enzymes (AST, ALT)
- Follow-Up Labs:
- Fasting lipid panel in 1–3 months post-initiation or dose change, then every 3–12 months.
- Liver enzymes at 1–3 months in high-risk patients or those with abnormal baseline.
- Muscle Symptoms:
- If myalgia or weakness, check Creatine Kinase (CK).
- Stop statin if CK >10× ULN (rhabdomyolysis) or persistent severe muscle pain.
3. Non-Pharmacological (Lifestyle) Treatment
- Dietary Approaches
- DASH diet: Emphasize fruits, vegetables, whole grains, lean proteins, low-fat dairy.
- Replace animal fats with olive oil, rice bran oil, soybean oil.
- Limit trans fats (margarine), sugary drinks, and refined carbs.
- For triglyceride (TG) control: reduce sugar and alcohol intake.
- Physical Activity
- Moderate-intensity aerobic exercise improves LDL, HDL, TG.
- Smoking Cessation
- Essential to reduce overall CV risk.
- Weight Management
- Calorie restriction for overweight/obese individuals.
4. Pharmacological Treatment: How to Order
4.1 Statins (First-Line Agents)
- Mechanism: Inhibit HMG-CoA reductase, lowering LDL-C.
- Monitoring: Check liver enzymes (AST, ALT) at baseline and 1–3 months after starting.
- Intensity Classifications (high, moderate, low) typically based on % LDL reduction.
- Atorvastatin
- Start: 10–20 mg PO once daily
- Max: 80 mg/day
- Example order: Atorvastatin 20 mg tab, 1 tab PO once daily at bedtime
- Rosuvastatin
- Start: 5–10 mg PO once daily
- Max: 40 mg/day (caution >20 mg in Asians due to higher plasma levels)
- Example order: Rosuvastatin 10 mg tab, 1 tab PO once daily
- Simvastatin
- Start: 10–20 mg PO once daily
- Max: 40 mg/day (generally avoid 80 mg/day due to myopathy risk)
- Example order: Simvastatin 20 mg tab, 1 tab PO once daily at bedtime
- Pravastatin
- Start: 10–20 mg PO once daily
- Max: 40 mg/day
- Example order: Pravastatin 20 mg tab, 1 tab PO once daily at bedtime
Older Adults: Often begin with a moderate-intensity statin; consider lower starting doses if frail or multiple comorbidities.
4.2 Ezetimibe
- Mechanism: Inhibits intestinal cholesterol absorption; often used with statins if LDL not at goal.
- Dose: 10 mg PO once daily
- Example order: Ezetimibe 10 mg tab, 1 tab PO once daily
4.3 Fibrates (For High Triglycerides >500 mg/dL)
- Mechanism: Increase lipoprotein lipase activity, lowering TG.
- Common Agent: Fenofibrate
- Start: 100 mg PO once daily (micronized forms vary)
- Max: 200 mg/day depending on formulation
- Example order: Fenofibrate 160 mg tab, 1 tab PO once daily
- Gemfibrozil: Avoid combining with statins due to high myopathy risk.
4.4 PCSK9 Inhibitors
- Mechanism: Monoclonal antibodies reducing LDL-receptor breakdown → potent LDL-lowering.
- Agents: Alirocumab, Evolocumab
- Indication: High-risk or familial hypercholesterolemia not controlled on max tolerated statin + ezetimibe.
- Route: Subcutaneous injection every 2–4 weeks (dose per package instructions).
4.5 Bile Acid Sequestrants
- Mechanism: Bind bile acids in intestine, lower LDL but can raise TG.
- Agents: Cholestyramine, Colestipol, Colesevelam
- Older Adults: Often not preferred if TG are elevated; also may interfere with absorption of other drugs.
4.6 Others (Omega-3, Bempedoic Acid, Inclisiran)
- Omega-3 Fatty Acids: Useful for TG >500 mg/dL. Example order: Omega-3 (EPA/DHA) 2–4 g/day in divided doses.
- Bempedoic Acid: Oral LDL-lowering agent, typically add-on to statin + ezetimibe.
- Inclisiran (PCSK9 siRNA): SC injection every 6 months in certain high-risk, statin-intolerant patients.
5. Primary Prevention in Older Adults
- LDL-C ≥190 mg/dL:
- Start moderate → escalate to high-intensity statin if inadequate response.
- Familial Hypercholesterolemia:
- High-intensity statin → add ezetimibe → consider PCSK9 inhibitor if LDL goal not met.
- LDL <190 mg/dL + 10-year risk ≥10% (Thai CV Risk Score):
- Low- to moderate-intensity statin initially; titrate up if needed.
In older adults (>75 years), use moderate-intensity statin if no prior statin history. Balance benefits vs. side effects.
6. Secondary Prevention (Existing CVD)
- High-Intensity Statin for acute coronary syndrome, established coronary artery disease, or stroke/TIA with atherosclerotic disease.
- LDL Target:
- <55 mg/dL for coronary artery disease.
- <70 mg/dL for stroke/TIA with atherosclerosis.
- Add ezetimibe if LDL not controlled; consider PCSK9 inhibitor if still above target.
7. Special Considerations for Older Adults
- Functional Status: If significant frailty, multimorbidity, or limited life expectancy, consider stopping or reducing statins to minimize pill burden and side effects.
- Liver Enzyme Elevation: If AST/ALT >3× ULN or significant myalgias with CK elevation, hold statin and investigate.
- Medication Interactions: Polypharmacy is common—check for drug-drug interactions (e.g., certain antifungals, macrolides, grapefruit juice can raise statin levels).
- Renal Function: Some fibrates, statins, and newer agents need dose adjustments in CKD.
8. Putting It All Together: Example Prescriptions
- Older Adult, Primary Prevention (No known CVD, LDL 160 mg/dL, 10-year risk 12%):
- Atorvastatin 20 mg tab, 1 tab PO once daily at bedtime, recheck lipid panel in 6–8 weeks.
- Patient with Coronary Artery Disease, LDL 140 mg/dL
- Rosuvastatin 20 mg tab, 1 tab PO once daily, target LDL <55 mg/dL. If still high after 6–8 weeks, add Ezetimibe 10 mg tab, 1 tab PO once daily.
- High TG (>500 mg/dL)
- Start Fenofibrate 160 mg tab, 1 tab PO once daily, plus lifestyle changes (reduce sugar, alcohol).
- Muscle Pain on Statin
- Check CK; if mild, reduce statin dose or switch to lower-intensity statin (e.g., simvastatin 10 mg). If severe, hold statin temporarily.
9. Summary
- Lifestyle First: Diet (DASH), weight management, exercise.
- Statins: Mainstay therapy; choose intensity based on risk level and older adult considerations.
- Add-On Agents: Ezetimibe, PCSK9 inhibitors, fibrates for high TG.
- Monitor: Lipid panel in 1–3 months, watch liver enzymes and CK if suspicious of adverse effects.
- Older Adults: Individualize therapy, be mindful of polypharmacy, hepatic/renal function, and overall life expectancy.
By following these Thai-focused guidelines—starting at appropriate doses (e.g., “Atorvastatin 20 mg tab once daily”) and escalating or combining therapies based on lipid goals—clinicians can achieve safe and effective dyslipidemia management in older adults, reducing cardiovascular morbidity and mortality while minimizing treatment risks.